RxDoctor Payments Data

Robert Martin, MD

Cardiovascular Disease · Shreveport, LANPI 1801886585

Payments from drug & device makers

$6,123in general payments, 2019–2025

Across 240 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$937
  • Abiomed$835
  • Shockwave Medical, Inc$396
  • Medtronic$394
  • Pfizer$287
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$264
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,02498%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,123 in reported general payments places this provider in the 60th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$221,345
Medicare patients
809
Services billed
2,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban502$413,017
XareltoRivaroxaban241$209,980
EntrestoSacubitril/Valsartan205$187,165
JardianceEmpagliflozin211$177,695
CamzyosMavacamten11$94,719
NexletolBempedoic Acid55$37,343
Ezetimibe1,980$35,831
MultaqDronedarone Hcl27$29,824
Repatha SureclickEvolocumab33$21,556
NexlizetBempedoic Acid/Ezetimibe30$17,338
BrilintaTicagrelor21$14,684
VascepaIcosapent Ethyl39$12,146
Rosuvastatin Calcium926$10,061
Dabigatran EtexilateDabigatran Etexilate Mesylate41$9,313
Clonidine103$8,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$287$413,017502 claims
Johnson & JohnsonXarelto$25$209,980241 claims
NovartisEntresto$134$187,165205 claims
Boehringer IngelheimJardiance$116$177,695211 claims
E.r. Squibb & Sons, L.L.C.Camzyos$240$94,71911 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$154$54,68185 claims
Sanofi-aventis U.S. LLCMultaq$113$29,82427 claims
AstraZenecaBrilinta$99$14,68421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →